Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3259373 | 1.00 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL3122399 | 0.95 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL3132694 | 0.94 | REN (0.96) | RENKCNH2CYP3A4 | |
| SCHEMBL3122463 | 0.92 | REN (0.91) | RENKCNH2CYP3A4 | |
| SCHEMBL3251287 | 0.92 | REN (0.91) | RENKCNH2CYP3A4 | |
| SCHEMBL13268192 | 0.92 | REN (0.91) | RENKCNH2CYP3A4 | |
| SCHEMBL3034460 | 0.92 | REN (0.91) | RENKCNH2CYP3A4 | |
| SCHEMBL8163856 | 0.92 | REN (0.90) | RENKCNH2CYP3A4 | |
| SCHEMBL3124429 | 0.92 | REN (0.93) | RENKCNH2CYP3A4 | |
| SCHEMBL3126938 | 0.91 | REN (0.91) | RENKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076359-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-12-13 | — | — | US | claimed |
| EP-2097377-B1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2010-07-07 | — | — | EP | claimed |
| US-20100063091-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-03-11 | — | — | US | claimed |
| EP-0714510-A4 | NATURAL KILLER CELL-SPECIFIC ANTIGEN AND ANTIBODIES THAT IDENTIFY THE SAME | DANA FARBER CANCER INST INC (US) | 1999-06-09 | — | — | EP | claimed |
| US-5786160-A | MONOCLONAL ANTIBODIES, GLYCOPROTEINS AND IMMUNOLOGY | DANA-FARBER CANCER INSTITUTE (US) | 1998-07-28 | — | — | US | claimed |
| EP-0714510-A1 | NATURAL KILLER CELL-SPECIFIC ANTIGEN AND ANTIBODIES THAT IDENTIFY THE SAME | DANA FARBER CANCER INSTITUTE (US) | 1996-06-05 | — | — | EP | claimed |
| WO-1995006247-A1 | NATURAL KILLER CELL-SPECIFIC ANTIGEN AND ANTIBODIES THAT IDENTIFY THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1995-03-02 | — | — | WO | claimed |
| US-10267809-B2 | Biochemical markers for CVD risk assessment | NORDIC BIOSCIENCE A/S (DK) | 2019-04-23 | — | — | US | disclosed |
| US-20160282362-A1 | Biochemical Markers for CVD Risk Assessment | NORDIC BIOSCIENCE A/S (DK) | 2016-09-29 | — | — | US | disclosed |
| US-9359633-B2 | Biochemical markers for CVD risk assessment | NORDIC BIOSCIENCE A/S (DK) | 2016-06-07 | — | — | US | disclosed |
| EP-2538221-A2 | Biochemical markers for CVD risk assessment | Nordic Bioscience A/S (DK) | 2012-12-26 | — | — | EP | disclosed |
| EP-2538223-A2 | Biochemical markers for CVD risk assessment | Nordic Bioscience Imaging A/S (DK) | 2012-12-26 | — | — | EP | disclosed |
| EP-2538218-A2 | Biochemical markers for CVD risk assessment | Nordic Bioscience Imaging A/S (DK) | 2012-12-26 | — | — | EP | disclosed |
| WO-2004050673-A2 | METHODS FOR SYNTHESIZING POLYSACCHARIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-0714510-B1 | NATURAL KILLER CELL-SPECIFIC ANTIGEN AND ANTIBODIES THAT IDENTIFY THE SAME | DANA FARBER CANCER INST INC (US) | 2002-06-19 | — | — | EP | disclosed |
| US-6194549-B1 | PARTIALLY PURIFIED PREPARATION OF PEN5, A GLYCOPROTEIN PAIR; FOR DETECTING AND/OR REMOVING NATURAL KILLER CELLS FROM A MIXED POPULATION OF CELLS | DANA-FARBER CANCER INSTITUTE | 2001-02-27 | — | — | US | disclosed |
| EP-0714510-A4 | NATURAL KILLER CELL-SPECIFIC ANTIGEN AND ANTIBODIES THAT IDENTIFY THE SAME | DANA FARBER CANCER INST INC (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5786160-A | MONOCLONAL ANTIBODIES, GLYCOPROTEINS AND IMMUNOLOGY | DANA-FARBER CANCER INSTITUTE (US) | 1998-07-28 | — | — | US | disclosed |
| EP-0714510-A1 | NATURAL KILLER CELL-SPECIFIC ANTIGEN AND ANTIBODIES THAT IDENTIFY THE SAME | DANA FARBER CANCER INSTITUTE (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995006247-A1 | NATURAL KILLER CELL-SPECIFIC ANTIGEN AND ANTIBODIES THAT IDENTIFY THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063091-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 822/4885CYP3A4 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.